Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P52815
UPID:
RM12_HUMAN
Alternative names:
39S ribosomal protein L12, mitochondrial; 5c5-2
Alternative UPACC:
P52815; Q969U0; Q9HCA2; Q9UQJ3
Background:
Large ribosomal subunit protein bL12m, also known as 39S ribosomal protein L12, mitochondrial and 5c5-2, is a crucial component of the mitochondrial large ribosomal subunit. It plays a pivotal role in mitochondrial translation, as evidenced by its association with mitochondrial RNA polymerase to activate transcription (PubMed:23603806).
Therapeutic significance:
Combined oxidative phosphorylation deficiency 45, a mitochondrial disorder characterized by severe developmental delays, seizures, and brain lesions, is linked to variants affecting the gene encoding this protein. Understanding the role of Large ribosomal subunit protein bL12m could open doors to potential therapeutic strategies for this condition.